Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 5/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5904780 | 0.84 | PDE2A (0.42) | PDE2ANOTUMCASRHSP90AA1HSP90AB1 | |
| SCHEMBL5904860 | 0.82 | PDE2A (0.43) | PDE2ANOTUMCASRHSP90AA1HSP90AB1 | |
| SCHEMBL5904618 | 0.79 | NOTUM (0.40) | NOTUMCASRHSP90AA1HSP90AB1SRC | |
| SCHEMBL4100527 | 0.79 | NOTUM (0.49) | NOTUMCASRSRCBRAFKDR | |
| SCHEMBL6035925 | 0.76 | PTGS2 (0.40) | NOTUMCASRSRCBRAFKDR | |
| SCHEMBL5904543 | 0.76 | PDE2A (0.47) | PDE2ANOTUMCASRHSP90AA1HSP90AB1 | |
| SCHEMBL3206263 | 0.76 | NOTUM (0.40) | NOTUMCASRSRCBRAFKDR | |
| SCHEMBL3965779 | 0.76 | PARP1 (0.44) | PDE2ANOTUMCASRADORA3 | |
| SCHEMBL6034578 | 0.75 | TLR8 (0.44) | PDE2ANOTUMCASRSRCBRAF | |
| SCHEMBL6035689 | 0.73 | MEN1 (0.46) | CASRAADATADORA3TRPA1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241157-A1 | Heterocyclic ppar modulators | ELI LILLY AND COMPANY | 2006-10-26 | — | — | US | disclosed |
| EP-1585733-A1 | HETEROCYCLIC PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004063166-A1 | HETEROCYCLIC PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241157-A1 | Heterocyclic ppar modulators | PPARA, PPARG, PPARD | PDE2A 2672/4885NOTUM 274/4885CASR 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.